Xspray Pharma AB (0GHZ) Price & Analysis

1 Followers

0GHZ Stock Chart & Stats

kr15.14

kr0.00(0.00%)

At close: Jul 29 4:00 PM EDT

kr15.14

kr0.00(0.00%)

Day’s Range― - ―

52-Week Rangekr9.14 - kr31.90

Previous CloseN/A

Volume0.00

Average Volume (3M)1.58K

Market Cap

kr519.69M

Enterprise Valuekr645.43M

Total Cash (Recent Filing)kr179.91M

Total Debt (Recent Filing)kr147.30M

Price to Earnings (P/E)―

Beta-0.02

Next Earnings

Nov 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.86

Shares Outstanding47,416,573

10 Day Avg. Volume1,341

30 Day Avg. Volume1,576

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)2.00

Price to Sales (P/S)0.00

P/FCF Ratio-5.44

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-6.2

Revenue Forecast (FY)kr19.00M

Bulls Say, Bears Say

Bulls Say

Moderate LeverageSubstantial equity relative to debt gives Xspray a comparatively resilient capital structure for an early-stage biotech. Moderate leverage can preserve financing flexibility and reduce fixed obligations while the company advances candidates toward regulatory approval and potential partnerships.

Improving Loss TrendAlthough profitability remains deeply negative, the reduction in losses from the 2024 trough indicates some improvement in financial performance. If maintained, this trend could moderate the pace of capital consumption and extend the company’s ability to fund development activities.

HyNap Technology PlatformA technology platform focused on improved bioavailability and reduced food effects can support multiple drug candidates rather than a single asset. Formulating established medicines may also provide a defined development pathway and create licensing opportunities across specialty markets.

Bears Say

No Commercial RevenueThe absence of reported revenue shows that Xspray has not yet reached meaningful commercialization, leaving its economic model dependent on future approvals, partnerships, or licensing outcomes. This makes near- to mid-term financial performance highly sensitive to development execution.

Persistent Cash BurnSustained negative operating and free cash flow means the company is consuming cash to support operations and development rather than funding itself through internally generated resources. Continued outflows can constrain investment capacity and increase the importance of external financing.

External Funding DependenceDependence on external financing creates a durable risk because ongoing losses and cash outflows must be funded before meaningful commercialization begins. Higher leverage than in earlier years may further reduce flexibility if financing conditions become less supportive.

Xspray Pharma AB News

Xspray Pharma Targets Q4 2026 FDA Resubmissions for Dasynoc and Nilopki

Xspray Pharma AB ( ($SE:XSPRAY) ) has provided an update. Xspray Pharma has reiterated plans to resubmit New...

21d ago

Xspray Pharma Highlights CML Data Differentiating Dasynoc and Nilopki

The latest update is out from Xspray Pharma AB ( ($SE:XSPRAY) ). Xspray Pharma will showcase new clinical...

30d ago

Xspray Pharma to Showcase Commercial Oncology Strategy at Gothenburg Investor Update

Xspray Pharma AB ( ($SE:XSPRAY) ) has shared an update. Xspray Pharma is organizing an Investor Update in...

1M ago

Xspray Pharma to Hold Investor Update Alongside Key Leukemia Conference

Xspray Pharma AB ( ($SE:XSPRAY) ) has issued an update. Xspray Pharma is organizing an Investor Update in...

1M ago

Xspray Pharma Schedules Call After FDA Response on Lead Cancer Drug Dasynoc

Xspray Pharma AB ( ($SE:XSPRAY) ) has shared an update. Xspray Pharma has called a conference call for...

2M ago

Xspray Pharma Gets FDA Complete Response Letter on Dasynoc, Speeds Manufacturing for 2026 Resubmission

Xspray Pharma AB ( ($SE:XSPRAY) ) has shared an update. Xspray Pharma has received a Complete Response Letter...

2M ago

Xspray Pharma Bolsters Finances as FDA Decisions Loom for Nilopki and Dasynoc

The latest update is out from Xspray Pharma AB ( ($SE:XSPRAY) ). Xspray Pharma reported another loss-making quarter...

3M ago

Xspray Pharma Advances FDA Reviews for Nilopki and Dasynoc Amid Manufacturing Checks

An announcement from Xspray Pharma AB ( ($SE:XSPRAY) ) is now available. Xspray Pharma has provided a regulatory...

4M ago

Xspray Pharma Schedules Investor Call After FDA Letter on Nilopki

Xspray Pharma AB ( ($SE:XSPRAY) ) has shared an announcement. Xspray Pharma will host an English-language conference call...

5M ago

Xspray Pharma Hit by FDA Setback on Nilopki but Keeps HyNap Strategy on Track

The latest update is out from Xspray Pharma AB ( ($SE:XSPRAY) ). Xspray Pharma has received a Complete...

5M ago

0GHZ FAQ

What was Xspray Pharma AB’s price range in the past 12 months?

Xspray Pharma AB lowest share price was kr9.14 and its highest was kr31.90 in the past 12 months.

What is Xspray Pharma AB’s market cap?

Xspray Pharma AB’s market cap is kr519.69M.

When is Xspray Pharma AB’s upcoming earnings report date?

Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.

How were Xspray Pharma AB’s earnings last quarter?

Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -kr0.868 earnings per share for the quarter.

Is Xspray Pharma AB overvalued?

According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xspray Pharma AB pay dividends?

Xspray Pharma AB does not currently pay dividends.

What is Xspray Pharma AB’s EPS estimate?

Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Xspray Pharma AB have?

Xspray Pharma AB has 47,416,573 shares outstanding.

What happened to Xspray Pharma AB’s price movement after its last earnings report?

Xspray Pharma AB reported an EPS of -kr0.868 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Xspray Pharma AB?

Currently, no hedge funds are holding shares in GB:0GHZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.